Literature DB >> 11289016

Clostridium difficile infections in HIV-positive patients.

S Wongwanich1, S Ramsiri, M Kusum, P Warachit.   

Abstract

The prevalence of Clostridium difficile infections in HIV-positive patients with regard to the presence of its enterotoxin was investigated. Enzyme immunoassay (EIA, Meridian Diagnostic Inc) was used for the detection of C. difficile enterotoxin in stool specimens collected from 201 HIV-positive and 271 HIV-negative diarrheal patients. Culture was performed on cycloserine cefoxitin fructose agar. Chromosomal DNA types of C. difficile isolates were determined by pulsed-field gel electrophoresis (PFGE). In the HIV-positive group, C. difficile enterotoxin was found in 58.8% and 12.6% of diarrheal and non-diarrheal patients, repectively, whereas this toxin was found in 36.5% of HIV-negative-diarrheal patients. However, 13.6% of stool samples were negative by toxin assay, but were positive for C. difficile by culture and latex agglutination test. Among 11 isolates from both HIV-positive and HIV-negative patients, 6 patterns of PFGE type were observed: A, B, C, D, E and F.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11289016

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  3 in total

1.  Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.

Authors:  T Peláez; L Alcalá; R Alonso; M Rodríguez-Créixems; J M García-Lechuz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 2.  Clostridium difficile infection in the Lao People's Democratic Republic: first isolation and review of the literature.

Authors:  Elaine Cheong; Tamalee Roberts; Sayaphet Rattanavong; Thomas V Riley; Paul N Newton; David A B Dance
Journal:  BMC Infect Dis       Date:  2017-09-21       Impact factor: 3.090

3.  Epidemiology of Clostridium difficile infection in Asia.

Authors:  Deirdre A Collins; Peter M Hawkey; Thomas V Riley
Journal:  Antimicrob Resist Infect Control       Date:  2013-07-01       Impact factor: 4.887

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.